Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04909541 · ClinicalTrials.gov registry record
Development of a New Canadian Endourology Group Stent Symptom Score
A clinical trial of Urologic Diseases, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).
- Recruiting
- Registry status
- 180
- Enrollment target
- 9
- Study locations
NCT04909541: Recruiting study of Urologic Diseases, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).
NCT04909541 is a study of Urologic Diseases that is actively recruiting participants, run by Centre hospitalier de l'Université de Montréal (CHUM). The registered enrollment target is 180 participants, above the 104-participant average among 11 other Urologic Diseases trials with a reported enrollment target (73% higher). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04909541, a study of Urologic Diseases, is actively recruiting participants, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).
- RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 9
- Study locations
Study Summary
Placement of a ureteral stent is a common urological intervention. For decades there was no valid measures available to assess quality of life issues in patients with ureteral stents, which has hampered the understanding of such symptoms and their true impact. In order to improve the outcomes associated with the placement of a stent, a validated tool is needed to measure its impact and the amount of undesirable effects it produces on patients requiring the placement of a stent. In 2003, the team of the Bristol Urological Institute developed a validated questionnaire called the: URETERAL STENT SYMPTOM QUESTIONNAIRE (USSQ). The questionnaire contains 38 items included in 6 sections. Despite the obvious need of a validated questionnaire, the latter remains unused by the community of peer urologists. Many of urologists consider it too long to be used in clinical practice and even for research purposes. This issue motivated the Canadian Endourology Group (CEG) to work collaboratively on the development of the CANADIAN ENDOUROLOGY GROUP STENT SYMPTOM SCORE (CEGSSS) in order to provide clinicians with a more useful and validated tool. To fulfill this objective, the CEG proceeds in three phases. Phase 1. A systematic, deliberative, and participatory approach mostly through face to face meetings, including patients, clinicians, and researchers in the field of Endourology to identify a minimum needs-based set of domains and items that are, clinically relevant to be included in the CEGSSS in order to ensure optimal uptake in the clinical setting. Phase 2. A pilot study to assess feasibility/acceptability and further refine the proposed set of items selected in phase 1 of the study. Phase 3. A multicentric prospective study to evaluate the validity, reliability and sensitivity to change of the CEGSSS. This research project is conducted by the Canadian Endourology Group (CEG), a panel of experts in the field of endourology in Canada. The CEG is a national member-based organizat
Conditions Studied
Interventions
- OTHER CEGSSS-Canadian Endourology Group Stent Symptom Score
Study Locations (9)
Ontario
- St. Michael's Hospital - University of Toronto - Toronto
- Toronto General Hospital - University Health Network (UHN) - Toronto
Quebec
- Centre Hospitalier de l'Université de Montréal (CHUM) - Montreal
- Royal Victoria Hospital- McGill University Health Centre - Montreal
California
- University of California, Los Angeles - Los Angeles
Ohio
- Cleveland Clinic - University of Toronto. - Mayfield Heights
Alberta
- Alberta University - Northern Alberta Urology Centre - Edmonton
British Columbia
- Vancouver General Hospital - Vancouver
Nova Scottia
- Dalhousie University - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2025-09-15 |
What NCT04909541 shows while recruiting
NCT04909541 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 104-participant average among 11 other Urologic Diseases trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Urologic Diseases appearing as the primary indexed condition, and to 1 intervention - of which CEGSSS-Canadian Endourology Group Stent Symptom Score is the first listed.
NCT04909541 lists 9 locations in 7 states (Ontario, Quebec, California).
Frequently Asked Questions
What is clinical trial NCT04909541 about?
NCT04909541 is a clinical study titled "Development of a New Canadian Endourology Group Stent Symptom Score". Placement of a ureteral stent is a common urological intervention. For decades there was no valid measures available to assess quality of life issues in patients with ureteral stents, which has hampered the understanding of such symptoms and their true impact. In order to improve the outcomes associ...
What is the current status of trial NCT04909541?
This trial is currently recruiting. The enrollment target is 180 participants. The study started on 2022-05-15. Estimated completion is 2025-09-15.
What conditions does trial NCT04909541 study?
This clinical trial studies the following conditions: Urologic Diseases.
What interventions are being tested in trial NCT04909541?
The interventions under investigation include: CEGSSS-Canadian Endourology Group Stent Symptom Score (OTHER).
Who is sponsoring clinical trial NCT04909541?
This trial is sponsored by Centre hospitalier de l'Université de Montréal (CHUM), which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04909541 being conducted?
This trial has 9 study locations across California, Ohio, Alberta, British Columbia, Nova Scottia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urologic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04909541's enrollment target sits among peer trials
180 4th of 11 higher than 8 of 11 other Urologic Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urologic Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
RECRUITING · Phase 1
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
Patient Satisfaction of Virtual vs In-Person Workup and Treatment of Lower Urinary Tract Symptoms.
RECRUITING · NA
-
Trial for Reliability of Urodynamics SysTem
RECRUITING · NA
-
Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures
RECRUITING · NA
-
INTIBIA Pivotal Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI